Project Grant R21CA291676
Award Date 8/20/25
Completion Date 7/31/27
Dollars Obligated $411K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...
- This $147,486 Project Grant was awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine on December 1, 2025, with a completion date of April 20, 2027. The grant supports a novel immune tolerization strategy called RECON to investigate the trade-offs between oncogene pathogenicity and immunogenicity. The key objective is to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the dissection of genetic and...
- This federal Project Grant award of $680,598 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the Cullin-5 complex in regulating T cell dysfunction in cancer. The research aims to develop new therapeutic approaches to engineer T cells with durable effector function, by targeting the Cullin-5 complex to prevent T cell dysfunction caused by chronic tumor antigen stimulation. The award was provided to the...
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Baylor College of Medicine to investigate the role of the HP1BP3 protein in regulating chromatin remodeling and its impact on tumor growth in high-grade glioma, the most common malignant adult brain cancer. The research aims to define epigenomic dysregulations that promote glioma growth and determine the mechanisms by which these alterations drive tumorigenesis....
- The National Cancer Institute (NCI) awarded a $678,723 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Baylor College of Medicine, located in Texas, USA. The project aims to ascertain the pathobiological role and translational significance of non-proteolytic ubiquitination of Programmed Death Ligand 1 (PD-L1) in evading tumoricidal T cells and improving cancer care, with a focus on lung cancer. The award period extends from February 21, 2025 to January 31, 2030....
- The National Cancer Institute (NCI) awarded a $220,340 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Baylor College of Medicine, effective July 31, 2024 through March 31, 2025. The grant supports a research project titled "Targeting the RNA Helicase DDX6 in Acute Myeloid Leukemia". The project aims to conduct innovative research on acute myeloid leukemia (AML), an aggressive blood cancer, with a focus on understanding the role of the RNA helicase DDX6 and developing new...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The National Cancer Institute awarded a $148,050 Project Grant under the Cancer Research Manpower federal grant program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports research to study the role of the APOBEC3 family of cytosine deaminases in driving genomic instability and mutagenesis in lung cancer. The project aims to identify the specific APOBEC3 enzymes responsible for lung cancer mutagenesis and develop novel tools to measure APOBEC3 activity. This research...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...